Collegium Pharmaceutical

US · COLL #3535 by market cap Listed 2015

21.93 +0.05 +0.23%

Live - 5344 symbols - heartbeat 30s ago · 2026-10-08 08:33

Pre-market 22.01 +0.36%

After-hours 21.93 0.00%

Market cap: 679.81M
P/E (TTM): 17.27
P/B: 2.18
EPS: 1.73
Div yield: 0.00%
52W pos: 2%

Reader sentiment Are you bullish or bearish on COLL?

Anonymous reader poll. Unscientific, not investment advice.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Founded: 2002
CEO: Mr. Vikram Karnani
Employees: 423
Headquarters: Stoughton, Massachusetts, United States of America
Fiscal year end: 12-31
Website: collegiumpharma.com

Company profile

Exchange: US
Symbol: COLL
Market-cap rank: #3535
Listing date: 2015-05-07
Market cap: 679.81M
Float cap: 631.41M
Shares out: 31.00M
Float shares: 28.79M

Sectors & themes

Best Growth Stocks Drug Manufacturers - Specialty & Generic Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:33:16 · For reference only, not investment advice and not tailored to your situation.